Topics:
Genitourinary Cancers • Medical Oncology
For patients who have completed up-front docetaxel for metastatic castration-sensitive prostate cancer, should they proceed to abiraterone before the development of castration resistance?
Two recent studies show benefit to up-front abiraterone for metastatic castration-sensitive prostate cancer, although these studies used control arms of ADT alone rather than ADT + docetaxel. While we await further studies, what will your clinical practice be?